格隆汇11月13日|安进公司周三澄清,其试验性减肥药与骨密度变化之间没有联系,第一阶段的研究结果并不表明存在任何骨安全问题,也没有改变我们对MariTide前景的信心。此前Cantor Fitzgerald的分析师称,他们对安进旗下MariTide的早期数据进行的审查显示,该药物导致了骨密度下降,此后该公司股价在周二跌7%,市值跌去了120多亿美元。然而,至少有四位分析师表示,这种担忧被夸大了,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.